RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Other Events
Item 8.01
|
Other Events. |
On April 28, 2017, Radius Health, Inc. (the Company) issued a
press release announcing U.S. Food and Drug Administration (FDA)
approval of TYMLOS (abaloparatide) injection for the treatment of
postmenopausal women with osteoporosis at high risk for fracture
defined as history of osteoporotic fracture, multiple risk
factors for fracture, or patients who have failed or are
intolerant to other available osteoporosis therapy.A copy of the
press release is filed as Exhibit 99.1 and is incorporated herein
by reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated April 28, 2017. |
About RADIUS HEALTH, INC. (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer. RADIUS HEALTH, INC. (NASDAQ:RDUS) Recent Trading Information
RADIUS HEALTH, INC. (NASDAQ:RDUS) closed its last trading session up +0.74 at 39.46 with 613,059 shares trading hands.
